Safety of administration of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, before curative-intent treatment in patients with HPV16+ oropharyngeal squamous cell carcinoma.Sidharth V. Puram, Douglas R. Adkins, Jason T. Rich et al.|Journal of Clinical Oncology|2025Cited by 4
Phase 2 trial of three schedules of CUE-101 administered before surgery or chemoradiotherapy in HLA-A*0201 positive patients with HPV16+ OPSCC.Jesse M. Zaretsky, Douglas Adkins, Jessica Ley et al.|Journal of Clinical Oncology|2023Cited by 2
Characterization of dynamic changes in tumor-infiltrating lymphocytes (TIL) after neoadjuvant administration of CUE-101, an HPV16 E7-HLA-IL2 fusion protein, to patients with HPV+ locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC).Jesse M. Zaretsky, Sidharth V. Puram, Riley Mullins et al.|Journal of Clinical Oncology|2025Cited by 0